Pembrolizumab (Keytruda®) in combination with chemotherapy with or without bevacizumab for the treatment of persistent, recurrent, or metastatic cervical cancer. Update July 2022

Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) in combination with chemotherapy with or without bevacizumab for the treatment of persistent, recurrent, or metastatic cervical cancer. Update July 2022. Oncology Fact Sheet Nr. 91.

[thumbnail of Oncology Fact Sheet Nr.91_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
127kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WP Gynaecology > WP 470-480 Cervix uteri. Cervix diseases
Language:	English
Series Name:	Oncology Fact Sheet Nr. 91
Deposited on:	25 Apr 2022 14:59
Last Modified:	26 Jul 2022 14:50

Repository Staff Only: item control page